52 Week Range
As of on the Bolsa de Valores do Estado de Sao Paulo ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Ontex completes acquisition of personal hygiene business of Hypermarcas
Ontex agrees to buy personal hygiene business of Hypermarcas
Hypermarcas SA to propose dividend payment
Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.
Biotechnology & Drugs
R Nova Cidade. 404
Luiz Eduardo Violland
Chairman of the Board
Claudio Bergamo dos Santos
Chief Executive Officer, Member of the Executive Board
Martim Prado Mattos
Chief Financial Officer, Chief Controllership Officer, Member of the Executive Board
Vivian Karina Trujillo Angiolucci
Chief Operating Officer, Member of the Executive Board
Breno Toledo Pires de Oliveira
Investor Relations Officer, Member of the Executive Board
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The controlling shareholder of Brazil's Hypera SA is in initial talks about a plea deal, Brazil's Valor Economico newspaper reported on Wednesday, as the pharmaceutical company continues an internal probe into alleged corruption.
Quarterly profit at Hypera SA , Brazil's largest listed producer of over-the-counter medicine, rose 22.3 percent on a yearly basis in the second quarter as revenues increased more than 10 percent due to higher overall sales.
Brazilian pharmaceuticals company Hypera SA said on Wednesday that its board had appointed an independent committee to investigate alleged corruption by former executives.
Brazilian pharmaceutical company Hypera SA is in talks to agree to a leniency deal with prosecutors that could include a 2 billion reais ($540 million) fine, newspaper Valor Economico reported on Thursday, an agreement that Hypera denied.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.